Hazlin John sold $2.3M of CL

Hazlin John (Chief Growth Officer) sold 23,376 shares of COLGATE PALMOLIVE CO (CL) at $99.15 ($2.32M total) on 2026-11-04.

Original reporting
SEC EDGAR · Hazlin John
Published Nov 6, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CL
Bearish
medium confidence
Mentioned
$CL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which can influence short‑term price action.

02

Market read

A C-level insider sold $2.3M of stock, a modest but noteworthy event for traders monitoring insider activity.

03

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 6/10Novelty 5/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CLBearishMedium confidence
Context

Chief Growth Officer Hazlin John sold 23,376 shares of Colgate-Palmolive for $2.3M on 2026-11-04.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

A $2.3M sale by a C-level officer is material enough to prompt short‑term selling, though the amount is modest.

Market effects

Minimal impact on consumer staples sector; insider sales are routine.

U.S. market only; no broader regional effect.

Low; does not affect global markets.

Counterpoint

The sale could be a routine portfolio rebalancing, not a lack of confidence.

Key entities

  • Colgate-Palmolive Co.

    U.S. consumer staples company whose ticker is CL.

  • Hazlin John

    Chief Growth Officer of Colgate-Palmolive, reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLMed

BofA raises Colgate-Palmolive stock price target to $105 on earnings

BofA Securities raised its price target for Colgate-Palmolive (NYSE:CL) to $105 from $100, citing strong earnings and updated fiscal 2026 guidance. The company reported Q3 earnings of $0.97 per share, exceeding estimates, with revenue of $5.37 billion. Colgate updated its outlook, expecting 4% to 5% net sales growth and 5% to 7% earnings growth. Analysts from UBS and Wells Fargo also raised their price targets.

$CLMedAI 8/10

Wells Fargo raises Colgate-Palmolive stock price target on solid Q3

Wells Fargo raised its price target for Colgate-Palmolive (NYSE:CL) to $95 from $90, citing solid Q3 2026 results. The firm noted strong performance despite macroeconomic challenges and inflation. CL's P/E ratio is 37.77, and it is considered overvalued. Q3 earnings beat expectations with $0.97 EPS on $5.37B revenue. UBS also raised its target to $112, highlighting strong margins.

$CLMed

UBS raises Colgate-Palmolive stock price target on margin strength

UBS raised its price target for Colgate-Palmolive (CL) to $112 from $106, citing strong Q3 earnings, revenue, and margins. The company beat EPS estimates and raised 2026 guidance. UBS expects continued sales growth despite inflation and FX headwinds, though the stock is slightly overvalued. CL reported Q3 adjusted EPS of $0.97 on revenue of $5.37B, exceeding expectations.

$CLMed

Colgate-Palmolive Co (CL) (Q3 2026) Earnings Call Highlights: Broad-Based Organic

Colgate-Palmolive (CL) reported Q3 2026 earnings, highlighting 6.5% organic growth in Hills pet food and strong volume leverage. CEO Noel Wallace attributed margin gains to pricing, innovation, and ad spend efficiency. CFO Stan Sutula noted material cost headwinds offset by productivity and pricing. Latin America grew 6%, with Brazil up double-digits. US toothpaste showed slight improvement, with more pricing expected.

$CLHighAI 8/10

Colgate-Palmolive Company Q3 2026 Earnings Call Summary

Colgate-Palmolive reported Q3 2026 earnings, highlighting organic growth in emerging markets and Europe. Gross margin expansion was driven by pricing strategy and manufacturing leverage. The company is transitioning its U.S. go-to-market structure and integrating AI for revenue growth. Hill's Pet Nutrition saw strong performance in high-growth segments.

$CLHighAI 8/10

Colgate-Palmolive Q3 Earnings Call Highlights

Colgate-Palmolive (CL) reported Q3 earnings, noting elevated commodity and logistics costs. Hill's Pet Nutrition saw 6.5% organic sales growth, driven by cat food and wet food. U.S. toothpaste market share shows early improvement. Latin America grew 6%, with Brazil up double digits. Asia-Pacific rose 5%, led by India. Full-year cost inflation is estimated at $300M. The company plans to provide 2027 guidance in Q1 next year.